Supplement encyclopedia

Boron

Boron is a chemical element found in food and included in some dietary supplements.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • In adults with knee discomfort, calcium fructoborate at 110 mg of the complex twice daily for two weeks may relieve pain and discomfort. Compared with placebo, the total score for pain, stiffness and limitations in everyday activities fell more, as did a separate pain score.
  • In a separate 90-day study, adults with knee discomfort reported that everyday activities were easier from day 30 with 216 mg calcium fructoborate in the morning or 108 mg twice daily compared with placebo. This possible help with usual activities was described in a supplementary analysis of participants' self-ratings.
  • In female students with moderate or severe primary menstrual pain, pain lasted an average of 2.74 hours in the second cycle versus 4.08 hours with placebo—a possible benefit is less time in pain. The study used capsules containing 10 mg elemental boron as sodium tetraborate daily from two days before menstruation through the third day of bleeding over two cycles.
  • The same regimen showed no clear advantage over placebo for reducing menstrual pain intensity. The final score was lower—4.35 versus 5.87 out of 10—but improvement from baseline did not differ convincingly between groups.
  • For increasing bone density, no advantage over placebo was found with 3 mg elemental boron daily as a citrate, aspartate and glycinate mixture over 10 months in young women aged 18–25.
  • For increasing strength, fat-free mass and testosterone in young bodybuilders, no advantage over placebo was found over seven weeks of training: the studied tablet contained a measured 2.49 mg of boron daily.

[1] [2] [3] [4] [5] [6] [7]

What was studied

  • Two separate calcium fructoborate trials lasting 14 and 90 days assessed possible help with knee discomfort. Several scales and a later analysis of the longer trial describe these same participant groups.
  • Three other trials concerned bone density in female students, strength-training results in men and menstrual pain in female students. This helps identify the relevant goal and find the result for the corresponding group below.

[1] [2] [3] [4] [5] [6] [7]

Which forms were considered

  • Calcium fructoborate was studied for knee discomfort; its mass differs from the amount of boron itself. The specific material assessed by EFSA contains 2.5–2.9% boron, so checking the amount on a label requires the composition of that particular product.
  • The bone-density study used a boron citrate, aspartate and glycinate mixture, while the chemical composition of the tablet in the sports trial was unknown. The sports tablet measured 2.49 mg boron although its label stated 5 mg: studied doses should be compared by the amount of the element itself.
  • The menstrual-pain study used capsules containing 10 mg elemental boron from 88.5 mg sodium tetraborate. This exact description of the tested form and dose basis helps distinguish it from other supplements.
  • The relative bioavailability of different boron forms is unknown. These data cannot identify a form that is demonstrably better absorbed than the others.

[1] [2] [3] [4] [5] [6] [7] [8]

How to get it from food

  • Boron can be obtained from familiar plant foods: fruit, vegetables, legumes and nuts. Avocados, apples, broccoli and peanuts can help diversify sources.
  • Half a cup of raw diced avocado contains about 1.07 mg boron, and half a cup of boiled chopped broccoli about 0.20 mg. These reference portions help compare foods' contributions to the diet.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Bone mineral densityIn young women, no clear difference in bone density versus placebo was found over 10 months.No convincing between-group difference in bone mineral density was found.
1/4 Very lowEstimate precision: Very serious limitation: 28 women divided into cells of 5–10; no precise between-group estimate of change or interval to rule out a meaningful effect. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: single blinding; allocation concealment and blinding of the bone-density assessor are unclear; objective measurement reduces reporting-distortion risk.
11 trialEffects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes ↗28 female students aged 18–25, including 17 athletes and 11 sedentary students
  1. Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes ↗
Total WOMAC scoreAfter two weeks, the total WOMAC score for knee pain, stiffness and function fell by 13.73 points more than with placebo.Difference in WOMAC changes on day 14: −13.73 points (95% CI −19.28…−8.19) between calcium fructoborate and placebo; on day 7: −5.30 (95% CI −10.84…0.24), p=0.061.
2/4 LowEstimate precision: Small sample; for some outcomes, between-group effect size and CI are absent from the available package. Consistency of findings: One relevant trial per outcome; reproducibility not assessed. Applicability to the specified group: Limited to the specified population, form, dose and duration; do not transfer to other groups or products. Possible publication bias: Undetermined with a single study. Study methods: Limited assessment: a full independent RoB 2 was not performed; some allocation, selective reporting and attrition methods are unknown. Commercial ties and retrospective registration were disclosed for the knee trial.
11 trialShort-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗60 adults with self-reported knee discomfort
  1. Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗
Total McGill Pain Questionnaire scoreAfter two weeks, the McGill pain score fell by 8.9 points more than with placebo.Difference in changes on day 14: −8.9 points, 95% CI −12.32…−5.48; on day 7: −5.8 points, p=0.0009.
2/4 LowEstimate precision: Serious limitation: 60 participants; the confidence interval excludes zero, but the threshold for meaningful benefit and its persistence in this group are unknown. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: commercial and patent interests, retrospective registration, unclear allocation concealment and subjective assessment.
11 trialShort-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗60 adults with self-reported knee discomfort
  1. Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake recommendationsNo RDA, AI or EAR has been established for boron: an essential function in humans has not yet been identified. Boron comes from food, especially plant foods.
Intake and studied regimensThe relative bioavailability of boron forms is unknown. The specific calcium fructoborate material assessed by EFSA contains 2.5–2.9% boron, usually 2.7%. In 220 mg of this material there is about 5.9 mg boron, with a specification maximum of about 6.4 mg; this conversion applies only to the assessed material.

Boron - Health Professional Fact Sheet ↗

Guidance for each goal

Bone mineral density1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: 28 women divided into cells of 5–10; no precise between-group estimate of change or interval to rule out a meaningful effect. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: single blinding; allocation concealment and blinding of the bone-density assessor are unclear; objective measurement reduces reporting-distortion risk.

In young women, no clear difference in bone density versus placebo was found over 10 months.

Study findings. In young women, no clear difference in bone density versus placebo was found over 10 months.

Studied regimen3 mg elemental boron daily in Tri-BoronCitrate, aspartate and glycinate chelates
Duration and population10 months28 female students aged 18–25, including 17 athletes and 11 sedentary students

Comparison: Cornstarch capsules; athletes and sedentary women were present in both groups

Total WOMAC score2/4 LowRead moreCollapse
Confidence
2/4 LowEstimate precision: Small sample; for some outcomes, between-group effect size and CI are absent from the available package. Consistency of findings: One relevant trial per outcome; reproducibility not assessed. Applicability to the specified group: Limited to the specified population, form, dose and duration; do not transfer to other groups or products. Possible publication bias: Undetermined with a single study. Study methods: Limited assessment: a full independent RoB 2 was not performed; some allocation, selective reporting and attrition methods are unknown. Commercial ties and retrospective registration were disclosed for the knee trial.

After two weeks, the total WOMAC score for knee pain, stiffness and function fell by 13.73 points more than with placebo.

Study findings. After two weeks, the total WOMAC score for knee pain, stiffness and function fell by 13.73 points more than with placebo.

Studied regimen110 mg of the complex twice dailyCalcium fructoborate
Duration and population14 days60 adults with self-reported knee discomfort

Comparison: Placebo

Total McGill Pain Questionnaire score2/4 LowRead moreCollapse
Confidence
2/4 LowEstimate precision: Serious limitation: 60 participants; the confidence interval excludes zero, but the threshold for meaningful benefit and its persistence in this group are unknown. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: commercial and patent interests, retrospective registration, unclear allocation concealment and subjective assessment.

After two weeks, the McGill pain score fell by 8.9 points more than with placebo.

Study findings. After two weeks, the McGill pain score fell by 8.9 points more than with placebo.

Studied regimen110 mg calcium fructoborate twice daily, compound massCalcium fructoborate
Duration and population14 days60 adults with self-reported knee discomfort

Comparison: Placebo

Self-rated everyday physical function1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Serious limitation: no usable between-group contrast or confidence interval; magnitude and clinical importance are unknown. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns self-rated everyday activity in the adults studied, not objective mobility or the 14-day trial result. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Very serious limitation: a sponsor-linked supplementary exploratory analysis of many scales, items, regimens and time points is not a prespecified confirmatory result.

In a supplementary analysis, participants reported better everyday function from day 30 compared with placebo.

Study findings. In a supplementary analysis, participants reported better everyday function from day 30 compared with placebo.

Studied regimen216 mg calcium fructoborate in the morning or 108 mg twice daily, compound massCalcium fructoborate
Duration and population90 days; supplementary analysis from day 30120 adults with self-reported knee discomfort, 40 in each of three groups

Comparison: Placebo; the once-daily group also received evening placebo

Total plasma testosterone1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group. In Naghii 2011, eight men received placebo then boron without a parallel control; this is neither an independent replication nor a contradiction of this comparison. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and concealment unclear; baseline training, calories and carbohydrates differed.

No additional change in total testosterone versus placebo was found.

Study findings. No additional change in total testosterone versus placebo was found.

Studied regimenMeasured 2.49 ± 0.12 mg elemental boron in the daily tablet; label stated 5 mgTablet, chemical form unknown
Duration and population49 days, or 7 weeks19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week

Comparison: Milk-protein placebo tablet containing 0.002 ± 0.001 mg boron; training in both groups

Free plasma testosterone1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group. In Naghii 2011, eight men received placebo then boron without a parallel control; this is neither an independent replication nor a contradiction of this comparison. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training and diet differed.

No difference in free testosterone versus placebo was found.

Study findings. No difference in free testosterone versus placebo was found.

Studied regimenMeasured 2.49 ± 0.12 mg elemental boron in the daily tablet; label stated 5 mgTablet, chemical form unknown
Duration and population49 days, or 7 weeks19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week

Comparison: Milk-protein placebo tablet containing 0.002 ± 0.001 mg boron; training in both groups

Squat and bench-press strength1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group, so between-trial consistency cannot be assessed. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training differed, and complete-case analysis after injuries further limits strength assessment, especially the squat.

No additional gain in squat and bench-press strength versus placebo was found.

Study findings. No additional gain in squat and bench-press strength versus placebo was found.

Studied regimenMeasured 2.49 ± 0.12 mg elemental boron in the daily tablet; label stated 5 mgTablet, chemical form unknown
Duration and population49 days, or 7 weeks19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week

Comparison: Milk-protein placebo tablet containing 0.002 ± 0.001 mg boron; training in both groups

Fat-free body mass1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: groups of no more than 10 and 9; no usable confidence interval for the difference in changes, so substantial benefit or harm cannot be excluded. Consistency of findings: One independent trial; the 1994 publication concerns the same group, so between-trial consistency cannot be assessed. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: randomization and double blinding stated, but sequence and allocation concealment unclear; baseline training and diet differed, potentially affecting fat-free mass change.

No additional gain in fat-free mass versus placebo was found.

Study findings. No additional gain in fat-free mass versus placebo was found.

Studied regimenMeasured 2.49 ± 0.12 mg elemental boron in the daily tablet; label stated 5 mgTablet, chemical form unknown
Duration and population49 days, or 7 weeks19 bodybuilders aged 20–27 with at least one year of training experience, training four days a week

Comparison: Milk-protein placebo tablet containing 0.002 ± 0.001 mg boron; training in both groups

Menstrual pain intensity1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Very serious limitation: one small trial without a confidence interval for the group-by-time interaction or adjusted change; the longitudinal comparison does not distinguish an effect from no effect, and the final difference includes baseline imbalance. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: symptom-severity blocks and triple blinding strengthen the design, but allocation concealment is not described; 1 and 4 women withdrew without an analysis of all randomized women; ratings are subjective and multiple analyses were performed.

In the second cycle, pain scores were 4.35 versus 5.87 points; the between-group difference in changes was not statistically significant.

Study findings. In the second cycle, pain scores were 4.35 versus 5.87 points; the between-group difference in changes was not statistically significant.

Studied regimen10 mg elemental boron daily in 88.5 mg sodium tetraborateSodium tetraborate
Duration and populationTwo cycles: daily from two days before menstruation through the third day of bleedingFemale students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed

Comparison: Capsule containing 300 mg lactose

Duration of menstrual pain2/4 LowRead moreCollapse
Confidence
2/4 LowEstimate precision: Serious limitation: 113 analyzed; no confidence interval for the group-by-time interaction or adjusted effect; unadjusted results do not establish the precise magnitude. Consistency of findings: One relevant independent trial; consistency cannot be assessed, which alone is not a reason to downgrade. Applicability to the specified group: Directly concerns the specified group, intervention and outcome; no extrapolation beyond these is intended. Possible publication bias: Insufficient data to establish publication bias in one small evidence set; no separate downgrade. Study methods: Serious limitation: symptom-severity blocks and triple blinding strengthen the design, but allocation concealment is not described; 1 and 4 women withdrew without an analysis of all randomized women; ratings are subjective and multiple analyses were performed.

In the second cycle, pain lasted an average of 2.74 hours versus 4.08 hours with placebo.

Study findings. In the second cycle, pain lasted an average of 2.74 hours versus 4.08 hours with placebo.

Studied regimen10 mg elemental boron daily in 88.5 mg sodium tetraborateSodium tetraborate
Duration and populationTwo cycles: daily from two days before menstruation through the third day of bleedingFemale students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed

Comparison: Capsule containing 300 mg lactose

Safety and limitations

Excess may cause nausea, vomiting, diarrhea and severe poisoning. Adult long-term total-intake UL: EFSA 10 mg/day, US 20 mg/day; this is not a supplement dose or a threshold of certain harm. Adverse reproductive and developmental effects in animals were considered when setting the US upper level. These data do not describe the frequency of such effects in humans consuming the UL. Boron is eliminated mainly by the kidneys. Upper levels for healthy people do not establish safe intake in kidney disease. EFSA specifies a total UL of 10 mg/day for adults, including pregnant and breastfeeding women; EFSA 2021 did not assess the particular calcium fructoborate for these groups. EFSA upper levels for total boron intake from all sources: ages 1–3, 3 mg/day; ages 4–6, 4 mg/day; ages 7–10, 5 mg/day; ages 11–14, 7 mg/day; ages 15–17, 9 mg/day. No UL is established for infants. NIH lists no known clinically significant interactions; absence of known interactions does not establish compatibility of all doses and multi-ingredient products.

Boron - Health Professional Fact Sheet ↗ · Summary of Tolerable Upper Intake Levels for minerals ↗ · Safety of calcium fructoborate as a novel food ↗

Food sources

Boron in the table is elemental boron in food. NIH portion values are rounded; values per 100 g are approximate conversions using the corresponding USDA portion weight. Energy and weight are from USDA SR28, 2015. A supplement compound's mass must not be treated as the mass of boron it contains.

Fruit

Avocados, apples, pears, bananas, citrus fruit, melon and dried fruit contain boron.

Boron - Health Professional Fact Sheet ↗

Vegetables

Sources include broccoli and leafy vegetables, for example.

Boron - Health Professional Fact Sheet ↗

Legumes and nuts

Boron occurs in legumes and nuts, including peanuts.

Boron - Health Professional Fact Sheet ↗

Dairy products

Whole milk also contains boron.

Boron - Health Professional Fact Sheet ↗

Food composition

FoodGroupAmountServingCaloriesSources
Avocadoraw, flesh dicedFruit1.4267 mg boron, approximate / 100 g75 g · 1.07 mg boron, approximate · 120 kcal½ cup diced; weight from the corresponding USDA record.160 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Cantaloupe melonfresh flesh, dicedFruit0.175 mg boron, approximate / 100 g80 g · 0.14 mg boron, approximate · 27.2 kcal½ cup diced; weight from the corresponding USDA record.34 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Broccoliboiled, choppedVegetables0.2564 mg boron, approximate / 100 g78 g · 0.2 mg boron, approximate · 27.3 kcal½ cup chopped broccoli; weight from the corresponding USDA record.35 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Vegetables and Vegetable Products ↗
SpinachboiledLeafy vegetables0.1778 mg boron, approximate / 100 g90 g · 0.16 mg boron, approximate · 20.7 kcal½ cup boiled spinach; weight from the corresponding USDA record.23 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Vegetables and Vegetable Products ↗
Onionraw, choppedVegetables0.2 mg boron, approximate / 100 g10 g · 0.02 mg boron, approximate · 4 kcal1 tablespoon40 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Vegetables and Vegetable Products ↗
Whole milkwhole, 3.25% fatDairy products0.0164 mg boron, approximate / 100 g244 g · 0.04 mg boron, approximate · 148.84 kcal1 cup; weight from the USDA record.61 kcal / 100 gBoron - Health Professional Fact Sheet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Dairy and Egg Products ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes ↗Bone mineral density28 female students aged 18–25, including 17 athletes and 11 sedentary studentsCitrate, aspartate and glycinate chelates; 3 mg elemental boron daily in Tri-Boron; 10 months; comparison: Cornstarch capsules; athletes and sedentary women were present in both groupsIn young women, no clear difference in bone density versus placebo was found over 10 months.
Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study ↗Total WOMAC score: Total WOMAC score Total McGill Pain Questionnaire score: Total McGill Pain Questionnaire scoreTotal WOMAC score: 60 adults with self-reported knee discomfort Total McGill Pain Questionnaire score: 60 adults with self-reported knee discomfortTotal WOMAC score: Calcium fructoborate; 110 mg of the complex twice daily; 14 days; comparison: Placebo Total McGill Pain Questionnaire score: Calcium fructoborate; 110 mg calcium fructoborate twice daily, compound mass; 14 days; comparison: PlaceboTotal WOMAC score: After two weeks, the total WOMAC score for knee pain, stiffness and function fell by 13.73 points more than with placebo. Total McGill Pain Questionnaire score: After two weeks, the McGill pain score fell by 8.9 points more than with placebo.